NCT01914367View on ClinicalTrials.gov

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 25, 2013

Primary Completion Date

September 23, 2015

Study Completion Date

September 23, 2015

Conditions
Infection With Human Papillomavirus
Interventions
BIOLOGICAL

cervarix

3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm

BIOLOGICAL

Gardasil

3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm

Trial Locations (1)

9000

Ghent University Hospital, Ghent

All Listed Sponsors
lead

University Hospital, Ghent

OTHER

NCT01914367 - Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) | Biotech Hunter | Biotech Hunter